1. STAT3/IRF1 Pathway Activation Sensitizes Cervical Cancer Cells to Chemotherapeutic Drugs.

    Cancer Research 76(13):3872 (2016) PMID 27216197

    Neoadjuvant radio/chemotherapy regimens can markedly improve cervical cancer outcome in a subset of patients, while other patients show poor responses, but may encounter severe adverse effects. Thus, there is a strong need for predictive biomarkers to improve clinical management of cervical canc...
  2. Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine.

    Journal of Experimental Medicine 212(12):2057 (2015) PMID 26527802 PMCID PMC4647259

    Tumor initiation in the intestine can rapidly occur from Lgr5(+) crypt columnar stem cells. Dclk1 is a marker of differentiated Tuft cells and, when coexpressed with Lgr5, also marks intestinal cancer stem cells. Here, we show that Elp3, the catalytic subunit of the Elongator complex, is require...
  3. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

    Cell 162(5):1169 (2015)

  4. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

    Cell 162(1):146 (2015) PMID 26140595

    KRAS is one of the most frequently mutated oncogenes in human cancer. Despite substantial efforts, no clinically applicable strategy has yet been developed to effectively treat KRAS-mutant tumors. Here, we perform a cell-line-based screen and identify strong synergistic interactions between cell...
  5. Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis.

    PLoS ONE 10(10):e0140525 (2015) PMID 26489083 PMCID PMC4619354

    Current guidelines recommend immunosuppressive treatment (IT) in patients with primary sclerosing cholangitis (PSC) and elevated aminotransferase levels more than five times the upper limit of normal and elevated serum IgG-levels above twice the upper limit of normal. Since there is no evidence ...
  6. Frequency of TERT promoter mutations in primary tumors of the liver.

    Virchows Archiv. A. Pathological Anatomy and Hi... 465(6):673 (2014) PMID 25267585

    Transcriptional regulation of the TERT gene is a major cause of the cancer-specific increase in telomerase activity. Recently, frequent somatic mutations in the TERT promoter have been described in several tumor entities such as melanoma, glioblastoma, bladder cancer, and hepatocellular carcinom...
  7. Prognostic impact of perineural, blood and lymph vessel invasion for esophageal cancer.

    Histology and histopathology 29(11):1467 (2014) PMID 24819775

    With a median survival of ⟨22 months esophageal cancer is one of the most aggressive tumors, up to 20% of node negative patients develop systemic relapse. Studies investigating the prognostic impact of tumor-micro-invasion in blood (AI) and lymphatic vessels (LVI) as well as perineural invasion ...
  8. Morphological study of synovial changes in two-stage reconstructions of the infected hip and knee arthroplasties.

    BMJ Open 2(4) (2012) PMID 22893669 PMCID PMC3425892

    To study the morphological changes of the regenerating synovium in two-stage revision arthroplasty, which is the gold standard for treatment of periprosthetic joint infection. The authors analysed a series of synovial biopsies to examine morphological changes in healing periprosthetic tissues da...
  9. Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer.

    Human Pathology 41(3):358 (2010) PMID 19896697

    Cell division cycle 7 is a widely expressed protein kinase implicated in cell division, cell cycle checkpoint mechanisms, and cancer progression. To determine the relationship of cell division cycle 7 protein expression with tumor phenotype, molecular features and prognosis, 2197 highly characte...
  10. HER-2 amplification is highly homogenous in gastric cancer.

    Human Pathology 40(6):769 (2009) PMID 19269014

    Her-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab). The potential benefit of anti-Her-2 therapy is currently investigated in several other HER-2-amplified cancers including gastric cancer. Although HER-2 amplification occurs in more than 10% of gastric canc...